ArticleIranian journal of basic medical sciences2026
Sacubitril/Valsartan: Breaking barriers in uterine adhesion and boosting pregnancy outcomes by suppressing inflammation and fibrosis.
Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Intrauterine adhesion (IUA) enhances infertility and is primarily driven by inflammation and fibrosis. Sacubitril/Valsartan (Sac/Val), an angiotensin receptor-neprilysin inhibitor, exhibits anti-inflammatory and anti-fibrotic properties; however, its effects on IUA and reproductive outcomes have not been previously studied. Materials and Methods: A rat model of IUA was established by mechanical endometrial injury. Animals were treated orally with Sac/Val (100 mg/kg/day) for 10 days. Inflammatory cytokine expression, oxidative stress markers, histological changes, and fibrotic indices were evaluated. Endometrial regeneration, embryonic development, pregnancy outcomes, and extra-uterine adhesion formation were also assessed. Results: Sac/Val treatment significantly reduced uterine inflammation, oxidative stress, and collagen deposition, as evidenced by decreased expression of pro-inflammatory cytokines and pro-fibrotic markers. Histological analysis demonstrated improved endometrial regeneration, including increased gland numbers and endometrial thickness. In addition, Sac/Val enhanced embryonic development, improved pregnancy rates, increased the number of live offspring, shortened time to conception, and reduced extra-uterine adhesion formation. Conclusion: Sac/Val enhances regeneration of endometrium and pregnancy outcomes in a rat model of IUA, primarily through suppression of inflammation and fibrosis. Further preclinical and clinical studies are needed to determine the protective functions of Sac/Val for IUA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.